5 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
GSK GlaxoSmithKline PLC $39.21 $97.25B N/A
Article Searches
Emergent (EBS) Wins HHS Contract to Supply VIGIV Product http://www.zacks.com/stock/news/424736/emergent-ebs-wins-hhs-contract-to-supply-vigiv-product?cid=CS-ZC-FT-424736 Jun 04, 2019 - Shares of Emergent (EBS) rise after the company gets a 10-year HHS contract valued at roughly $535 million to dispense VIGIV product to the U.S. government for supporting its smallpox awareness drive.
Sanofi Partners Google to Build Healthcare Innovation Lab http://www.zacks.com/stock/news/431152/sanofi-partners-google-to-build-healthcare-innovation-lab?cid=CS-ZC-FT-431152 Jun 18, 2019 - Sanofi (SNY) signs a partnership pact with Google to develop a new virtual healthcare innovation lab for modernizing future medicines and healthcare services with sophisticated data technologies.
Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options http://www.zacks.com/stock/news/424909/glaxos-nucala-gets-chmp-nod-for-2-self-administered-options?cid=CS-ZC-FT-424909 Jun 05, 2019 - GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.
AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use http://www.zacks.com/stock/news/431009/astrazeneca-mercks-lynparza-wins-eu-nod-for-first-line-use?cid=CS-ZC-FT-431009 Jun 18, 2019 - AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.
Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs http://www.zacks.com/stock/news/432004/gilead-gild-teams-up-with-nurix-for-cancer-and-other-drugs?cid=CS-ZC-FT-432004 Jun 20, 2019 - Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.

Pages: 1

Page 1